A Phase Ib Study of Durvalumab (Medi4736) and Tremelimumab Following Radioembolization in Patients With Unresectable Locally Advanced Hepatocellular Carcinoma
Latest Information Update: 07 Oct 2025
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Yttrium-90
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 10 Sep 2025 Planned End Date changed from 25 Aug 2025 to 25 Feb 2026.
- 10 Sep 2025 Planned primary completion date changed from 25 Aug 2025 to 25 Feb 2026.
- 10 Sep 2025 Status changed from recruiting to active, no longer recruiting.